Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)

Organon

Status and phase: Completed; Phase 3

Conditions: Hyperlipidemia

Treatments: Drug: ezetimibe (+) simvastatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00651560

2008_008

MK0653A-148

0653A-148

Details and patient eligibility

About

This study is intended to allow physicians to check the superior clinical efficacy of Vytorin compared to atorvastatin, as the most adequate therapy using the ATP-III goals achievement and cardiovascular risk reduction in adult patients with dislipidemia.

Enrollment: 167 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients Who Voluntary Accept To Participate In The Study After Been Informed By The Doctor And Signed The Informed Consent Form.

Exclusion criteria

• Any Another Kind Of Contraindication For Use Of Statins
• Hypersensitivity To Any Of The Active Ingredients
• Increased Serum Hepatic Enzymes (Over 3 Times Only)
• Patients With Severe Hepatic Insufficiency
• Women who are Pregnant or Potentially Pregnant

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)